Fluoroquinolone treatment as a protective factor for 10-day mortality in Streptococcus pneumoniae bacteremia in cancer patients

• Published in: Scientific reports Vol. 11; no. 1; p. 3699
• Main Authors: Fontana, Naihma Salum, Ibrahim, Karim Yaqub, Bonazzi, P. R., Rossi, F., Almeida, S. C. G., Tengan, F. M., Brandileone, M. C. C., Abdala, E.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 12.02.2021; Nature Publishing Group; Nature Portfolio
• Subjects: 692/699/255/1318; 692/699/67; Antibiotics; Bacteremia; Cancer; Cancer therapies; Chemotherapy; Fever; Fluoroquinolones; Humanities and Social Sciences; Medical prognosis; Metastases; Mortality; multidisciplinary; Neutropenia; Patients; Polymicrobial bacteremia; Radiation therapy; Risk factors; Science; Science (multidisciplinary); Solid tumors; Streptococcus infections; Streptococcus pneumoniae; Vaccination
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-021-81415-0

To evaluate the prognostic factors in adult cancer patients with pneumococcal bacteremia, describe episode features and the phenotypic characteristics of the isolated strains. We evaluated the episodes in patients admitted to a cancer hospital between 2009 and 2015. The outcomes were defined as 48 h mortality and mortality within 10 days after the episode. The variables evaluated were: age, sex, ethnicity, ECOG, Karnofsky score, SOFA, cancer type, metastasis, chemotherapy, radiotherapy, neutropenia, previous antibiotic therapy, community or healthcare-acquired infection, comorbidities, smoking, pneumococcal vaccination, infection site, presence of fever, polymicrobial infection, antimicrobial susceptibility, serotype and treatment. 165 episodes were detected in 161 patients. The mean age was 61.3 years; solid tumors were the most prevalent (75%). 48 h and 10-day mortality were 21% (34/161) and 43% (70/161) respectively. The 48 h mortality- associated risk factors were SOFA and polymicrobial bacteremia; 10-day mortality-associated risk factors were fever, neutropenia, ECOG 3/4, SOFA and fluoroquinolones as a protective factor. Pneumococcal bacteremia presented high mortality in cancer patients, with prognosis related to intrinsic host factors and infection episodes features. Fluoroquinolone treatment, a protective factor in 10-day mortality, has potential use for IPDs and severe community-acquired pneumonia in cancer patients.